SNDX
Syndax Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow -8.7% ·
net new positions +6.2%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | 0 | 57.47M | $1.26B | +9 | −10 |
| Q1 2026 | 97 | +6 | 52.14M | $1.22B | +10 | −4 |
| Q4 2025 | 91 | -3 | 57.71M | $1.21B | — | −3 |
| Q3 2025 | 20 | +1 | 39.69M | $610.59M | +1 | — |
| Q2 2025 | 16 | +1 | 29.55M | $276.77M | +1 | — |
| Q1 2025 | 12 | -1 | 16.71M | $205.25M | — | −1 |
| Q4 2024 | 13 | +1 | 16.01M | $211.65M | +1 | — |
| Q3 2024 | 11 | -1 | 14.02M | $269.82M | — | −1 |
| Q2 2024 | 12 | — | 17.35M | $356.12M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 10.46M | — | $97.93M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 5.03M | — | $47.14M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 3.44M | -13.3% | $32.24M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Point72 Asset Management ✦ | 2.13M | -46.9% | $19.92M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.05M | +1.3% | $19.19M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Millennium Management ✦ | 1.60M | +272.9% | $14.97M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 1.43M | +126.8% | $13.41M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 837.70K | +22.9% | $7.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 644.54K | -18.2% | $6.04M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 640.00K | -78.0% | $5.99M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 556.97K | -28.6% | $5.22M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Marshall Wace ✦ | 232.12K | New | $2.17M | 0.0% | New | 1 | SEC ↗ ×3 |
| 13 | AQR Capital Management ✦ | 230.58K | -38.9% | $2.16M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 14 | Fidelity (FMR) ✦ | 160.92K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 15 | T. Rowe Price ✦ | 75.40K | +14.1% | $706,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Wellington Management ✦ | 34.09K | -5.2% | $319,207 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $2.17M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 244 holders, 99.11M shares, $2.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.